Keynote: Biotech at a Crossroads – Rethinking Innovation in a Shifting Landscape

Session details:

The biotech ecosystem is under pressure – from capital constraints to increasingly complex science. This session with a Lilly senior executive explores how the company is deploying a variety of conventional business development strategies as well as multiple bets on promising early science to augment its capabilities and pipeline to bring new medicines to patients. 

• Examine the strategic and operational headwinds facing early-stage biotech
• Learn how Lilly’s BD teams are developing flexible partnerships to help biotechs meet the moment at various stages of development
• Explore real-world examples of collaborative models that go beyond transactions—and redefine what meaningful progress looks like